Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Morphinans" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Neuroprotective properties of dextrorotatory morphinans
InactiveUS20050256147A1Effective anti-ParkinsonismAvoid production cutsBiocideNervous disorderMorphinansNeuroprotection
Owner:KNU IND COOPERATION FOUND
Processes for the synthesis of tertiary amines
The invention provides processes for the preparation of morphinans having a tertiary amine. In particular, the present invention provides processes for the formation of tertiary amine alkaloids by direct N-alkylation of secondary amine alkaloids, the processes co-mediated by an alkylating agent and a protic solvent or a mixture of a protic solvent and an aprotic solvent.
Owner:SPECGX LLC
N-demethylation of N-methyl morphinans
The present invention provides a synthetic process for the N-demethylation of N-methyl morphinans. In particular, the invention provides improved synthetic methods for the preparation of N-demethylated morphinan compounds that may be employed as starting materials, for example, commonly available N-methyl opiates such as oripavine and thebaine, and C(3)-protected hydroxy derivatives of oripavine.
Owner:SPECGX LLC
Substituted morphinans and the use thereof
The application is directed to compounds of Formula I:and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4a, and R4b are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
Owner:PURDUE PHARMA LP
Spirocyclic morphinans and their use
Owner:PURDUE PHARMA LP
Processes for the synthesis of tertiary amines
The invention provides processes for the preparation of morphinans having a tertiary amine. In particular, the present invention provides processes for the formation of tertiary amine alkaloids by direct N-alkylation of secondary amine alkaloids, the processes co-mediated by an alkylating agent and a protic solvent or a mixture of a protic solvent and an aprotic solvent.
Owner:SPECGX LLC
N-demethylation of N-methyl morphinans
The present invention provides a synthetic process for the N-demethylation of N-methyl morphinans. In particular, the invention provides improved synthetic methods for the preparation of N-demethylated morphinan compounds that may be employed as starting materials, for example, commonly available N-methyl opiates such as oripavine and thebaine, and C(3)-protected hydroxy derivatives of oripavine.
Owner:SPECGX LLC
Cytochrome P450 fusion protein
ActiveUS10006010B2Good flexibilityEfficient and rapid and easy assemblyAntibody mimetics/scaffoldsOxidoreductasesMorphinansCytochrome P450
This disclosure relates to the isolation of a nucleic acid molecule[s] that encode a novel cytochrome P450 and an oxidoreductase from a Papaver somniferum [P. somniferum] cultivar, transgenic cells transformed with said nucleic acid molecule and sequence variants thereof; and including methods for the production of intermediates in the production of morphinans.
Owner:THE UNIV OF YORK +1
Processes and Intermediates in the Preparation of Morphine Analogs via N-Demethylation of N-Oxides Using Cyclodehydration Reagents
InactiveUS20120283443A1Efficient conversionOrganic chemistryBulk chemical productionMorphinansOxymorphone
A high-yielding method for the N-demethylation of oxycodone- and oxymorphone-N-oxides by the reaction of these compounds with cyclodehydration reagents has been performed. This method has been utilized to improve the synthesis of various morphine analogs, such as naltrexone, nalbuphone and naloxone.
Owner:BROCK UNIVERSITY
Preparation of 6-Alpha-Amino N-Substituted Morphinans by Catalytic Hydrogen Transfer
The present invention provides processes for the stereoselective synthesis of 6-alpha-amino N-substituted morphinans. In particular, the invention provides processes for the reductive amination of 6-keto N-substituted morphinans by catalytic hydrogen transfer.
Owner:SPECGX LLC
Compositions and Methods For Making Alkaloid Morphinans
Methods that may be used for the manufacture of a class of chemical compounds known as morphinans, including neopine, are provided. Compositions useful for the synthesis of morphinans, including neopine, are also provided.
Owner:WILLOW BIOSCI INC
Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, Y, Z, and G are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I), and pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
![Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans](https://images-eureka.patsnap.com/patent_img/e507c652-00c4-46af-a263-e7910eafb8bb/US20170022213A1-20170126-C00001.png "Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans")
![Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans](https://images-eureka.patsnap.com/patent_img/e507c652-00c4-46af-a263-e7910eafb8bb/US20170022213A1-20170126-C00002.png "Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans")
![Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans](https://images-eureka.patsnap.com/patent_img/e507c652-00c4-46af-a263-e7910eafb8bb/US20170022213A1-20170126-C00003.png "Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans")
Owner:PURDUE PHARMA LP
Spirocyclic Morphinans and Their Use
The application is directed to compounds of Formula I′-Aespecially to compounds of Formula I-Aand pharmaceutically acceptable salts and solvates thereof, wherein R1a-R5a, Y, Z are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I′-A, and especially compounds of Formula I-A, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
Owner:PURDUE PHARMA LP
Methods Related to the Treatment of Neurodegenerative and Inflammatory Conditions
The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and / or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
Owner:UNITED STATES OF AMERICA
Methods related to the treatment of neurodegenerative and inflammatory conditions
The invention includes methods of neuroprotection, inducing release of neurotrophic factors, inhibiting the over-activation of innate immune cells, attenuating the toxin-induced death and / or damage of tissues, reducing inflammation, treating an inflammation-related condition, and inhibiting NADPH oxidase, that includes contacting or administering an effective amount of at least one compound of the invention that include: valproic acid, sodium butyrate, and salts thereof; opioid peptides; a peptide comprising the tripeptide GGF; and morphinans, such as naloxone, naltrexone, 3-hydroxy-morphinan and dextromethorphan.
Owner:UNITED STATES OF AMERICA
Processes for Preparing Morphinans and Intermediates Thereof
The present invention is directed to processes for the synthesis of morphinans. In particular, a process for cyclizing a β,γ-bicyclic ketone compound to form a nordihydrothebainone product using the Grewe cyclization reaction is improved by forming a reaction mixture comprising a β,γ-bicyclic ketone compound, a cyclizing acid and a water scavenging cyclization additive. In one embodiment, the Grewe transformation occurs in the presence of an acid anhydride as the cyclization additive. Further, the present invention is directed to processes for converting α,β-bicyclic ketone compounds (e.g., by-products of the Grewe cyclization reaction) to β,γ-bicyclic ketone compounds, wherein the β,γ-bicyclic ketone compounds may be recovered to further undergo Grewe cyclization and form the nordihydrothebainone product.
Owner:MALLINCKRODT INC
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Tandem Process for Preparing N-Alkyl Morphinans
The present invention provides processes for the preparation of N-alkyl morphinans without the isolation of nor-morphinan intermediates. In particular, the invention provides tandem hydrolysis / alkylation reactions for the synthesis of N-alkyl morphinans.
Owner:SPECGX LLC
Process for the Preparation of Hexahydroisoquinolines from 1,2,3,4-Tetrahydroisoquinolines
ActiveUS20090247756A1Organic chemistryBulk chemical productionSilver tetrafluoroborateBirch reduction
The present invention is directed to processes for the synthesis of morphinans. In particular, a process for the asymmetric reduction of an imine moiety in a 3,4-dihydroisoquinoline to produce a tetrahydroisoquinoline, followed by a Birch reduction to produce a hexahydroisoquinoline. In various embodiments, the 3,4-dihydroisoquinoline contains a phenol moiety protected with a labile protecting group. In other embodiments, the imine reduction reaction mixture contains silver tetrafluoroborate.
Owner:SPECGX LLC
Process for the preparation of morphine analogs via metal catalyzed n-demethylation/functionalization and intramolecular group transfer
The present application is directed to an efficient conversion of C-14 hydroxylated morphine alkaloids to various morphine analogs, such as naltrexone, naloxone and nalbuphone. One feature of this process is an intramolecular functional group transfer from the C-14 hydroxyl to the N-17 nitrogen atom following a palladium-catalyzed N-demethylation.
Owner:BROCK UNIVERSITY
Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Owner:MALLINCKRODT INC
Preparation of 6-Keto, 3-Alkoxy Morphinans
The present invention provides processes for the preparation of saturated 6-keto, 3-alkoxy morphinans from unsaturated 6-hydroxy, 3-hydroxy morphinans, In particular, the invention provides processes that utilize catalytic isomerization and alkylation reactions for the preparation of saturated 6-keto, 3-alkoxy morphinans.
Owner:MALLINCKRODT INC
Heterocycle-fused morphinans compounds, preparation method and use thereof
The invention discloses an aromatic or aliphatic heterocyclic condensed morphinan compound, a synthesis method thereof, and such applications thereof as opioid receptor agonist or anti-agonist in treating drug abuse and as novel painkiller. The general structural formula of the compound is shown in (I), wherein, R is H, straight chain or branch chain alkyl of C1 to C10, aromatic group or aliphatic heterocyclic or non-heterocyclic substituted alkyl; X is H, -OH, alkoxy, amido, substituted amido, carboxyl, ester group, aminoacyl; Y is H, -OH, alkoxyl, amido, substituted amido, etc., and Z is various substituted pentagon, hexagon or substituted pentagon, hexagon aromatic and aliphatic heterocycle.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Ring-contracted morphinans and the use thereof
The application is directed to compounds of Formula (I) or (IA) and pharmaceutically acceptable salts and solvates thereof, wherein R1 R2, R3 and G are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) or(IA), and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates. Certain compounds of the present invention are especially useful for treating pain.
Owner:PURDUE PHARMA LP
Heterocycle-fused morphinans compounds, preparation method and use thereof
The present invention discloses an aromatic or aliphatic heterocyclic condensed morphinan compound, a synthesis method thereof, and such applications thereof as opioid receptor agonist or anti-agonist in treating drug abuse and as novel painkiller. The general structural formula of the compound is shown in (I), wherein, R is H, straight chain or branch chain alkyl of C1 to C10, aromatic group or aliphatic heterocyclic or non-heterocyclic substituted alkyl; X is H, -OH, alkoxy, amido, substituted amido, carboxyl, ester group, aminoacyl; Y is H, -OH, alkoxyl, amido, substituted amido, etc., and Z is various substituted pentagon, hexagon or substituted pentagon, hexagon aromatic and aliphatic heterocycle.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com